Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2
Nucleoside/tide analogues (NAs) have long been used in the fight against viral diseases,
and now present a promising option for the treatment of COVID-19. Once activated to the 5 …
and now present a promising option for the treatment of COVID-19. Once activated to the 5 …
[HTML][HTML] Potential herb–drug interactions between anti-COVID-19 drugs and traditional Chinese medicine
L Ye, S Fan, P Zhao, C Wu, M Liu, S Hu, P Wang… - … Pharmaceutica Sinica B, 2023 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide. Effective treatments against …
syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide. Effective treatments against …
Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection
Remdesivir (RDV) is a nucleotide analog prodrug with demonstrated clinical benefit in
patients with coronavirus disease 2019 (COVID-19). In October 2020, the US FDA approved …
patients with coronavirus disease 2019 (COVID-19). In October 2020, the US FDA approved …
Discovery of GS-5245 (obeldesivir), an oral prodrug of nucleoside GS-441524 that exhibits antiviral efficacy in SARS-CoV-2-infected African green monkeys
Remdesivir 1 is an phosphoramidate prodrug that releases the monophosphate of
nucleoside GS-441524 (2) into lung cells, thereby forming the bioactive triphosphate 2-NTP …
nucleoside GS-441524 (2) into lung cells, thereby forming the bioactive triphosphate 2-NTP …
Phosphoramidate prodrugs continue to deliver, the journey of remdesivir (GS-5734) from RSV to SARS-CoV-2
RL Mackman - ACS Medicinal Chemistry Letters, 2022 - ACS Publications
Remdesivir (GS-5734) is a monophenol, 2-ethylbutylalanine phosphoramidate prodrug of a
1′-cyano-4-aza-7, 9-dideazaadenosine C-nucleoside (GS-441524) that is FDA approved …
1′-cyano-4-aza-7, 9-dideazaadenosine C-nucleoside (GS-441524) that is FDA approved …
Multi-omics for COVID-19: driving development of therapeutics and vaccines
M Guo, M Xiong, J Peng, T Guan, H Su… - National Science …, 2023 - academic.oup.com
The ongoing COVID-19 pandemic caused by SARS-CoV-2 has raised global concern for
public health and economy. The development of therapeutics and vaccines to combat this …
public health and economy. The development of therapeutics and vaccines to combat this …
[HTML][HTML] Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside
Remdesivir, a monophosphate prodrug of nucleoside analog GS-441524, is widely used for
the treatment of moderate to severe COVID-19. It has been suggested to use GS-441524 …
the treatment of moderate to severe COVID-19. It has been suggested to use GS-441524 …
Remdesivir: quo vadis?
E De Clercq - Biochemical Pharmacology, 2021 - Elsevier
Abstract Remdesivir (GS-5734, Veklury®) has remained the only antiviral drug formally
approved by the US FDA for the treatment of Covid-19 (SARS-CoV-2 infection). Its key …
approved by the US FDA for the treatment of Covid-19 (SARS-CoV-2 infection). Its key …
Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients …
Summary Background Remdesivir (Veklury, Gilead Sciences, Foster City, CA, USA) and
nirmatrelvir–ritonavir (Paxlovid, Pfizer, New York, NY, USA) were reported to improve the …
nirmatrelvir–ritonavir (Paxlovid, Pfizer, New York, NY, USA) were reported to improve the …
Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivir
D Yan, B Yan - Fundamental & Clinical Pharmacology, 2023 - Wiley Online Library
The COVID‐19 pandemic remains a major health concern worldwide, and SARS‐CoV‐2 is
continuously evolving. There is an urgent need to identify new antiviral drugs and develop …
continuously evolving. There is an urgent need to identify new antiviral drugs and develop …